Artiva Biotherapeutics (ARTV) Cash & Equivalents (2023 - 2026)

Artiva Biotherapeutics (ARTV) has reported Cash & Equivalents for 4 consecutive years, with $86.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents rose 185.52% year-over-year to $86.8 million; the TTM figure through Mar 2026 stood at $86.8 million (up 185.52% YoY), while the FY2025 annual figure was $26.7 million, down 33.64% from the prior year.
• Cash & Equivalents advanced to $86.8 million in Q1 2026 per ARTV's latest filing, from $26.7 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $123.0 million in Q3 2025 and bottomed at $26.7 million in Q4 2025.
• Historically, Cash & Equivalents has averaged $53.9 million across 4 years, with a median of $50.9 million in 2023.
• Annual changes were most pronounced in 2025 — Cash & Equivalents plunged 36.93% — and 2026, when it surged 185.52%.
• Artiva Biotherapeutics' Cash & Equivalents stood at $53.5 million in 2023, then slipped by 24.8% to $40.2 million in 2024, then tumbled by 33.64% to $26.7 million in 2025, then surged by 225.08% to $86.8 million in 2026.
• Business Quant data shows ARTV's Cash & Equivalents at $86.8 million in Q1 2026, $26.7 million in Q4 2025, and $123.0 million in Q3 2025.